Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - CTI BIOPHARMA CORP | Financial_Report.xls |
| EX-32 - EX-32 - CTI BIOPHARMA CORP | ctic-ex32_2014123111.htm |
| EX-12.1 - EX-12.1 - CTI BIOPHARMA CORP | ctic-ex121_201412316.htm |
| EX-21.1 - EX-21.1 - CTI BIOPHARMA CORP | ctic-ex211_201412319.htm |
| EX-31.1 - EX-31.1 - CTI BIOPHARMA CORP | ctic-ex311_2014123110.htm |
| EX-10.6 - EX-10.6 - CTI BIOPHARMA CORP | ctic-ex106_20141231464.htm |
| EX-10.4 - EX-10.4 - CTI BIOPHARMA CORP | ctic-ex104_20141231463.htm |
| EX-10.14 - EX-10.14 - CTI BIOPHARMA CORP | ctic-ex1014_201412311331.htm |
| EX-10.16 - EX-10.16 - CTI BIOPHARMA CORP | ctic-ex1016_201412312020.htm |
| EX-10.48 - EX-10.48 - CTI BIOPHARMA CORP | ctic-ex1048_201412311721.htm |
| EX-10.15 - EX-10.15 - CTI BIOPHARMA CORP | ctic-ex1015_201412311332.htm |
| 10-K - 10-K - CTI BIOPHARMA CORP | ctic-10k_20141231.htm |
| EX-31.2 - EX-31.2 - CTI BIOPHARMA CORP | ctic-ex312_201412317.htm |
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the incorporation by reference in the Registration Statement of CTI BioPharma Corp. (formerly known as Cell Therapeutics, Inc.) on Form S-3 (Nos. 333-108926, 333-134126, 333-149980, 333-149981, 333-152171, 333-157376, 333-160969, 333-163479, 333-161442, 333-177506, 333-182330, 333-183037, 333-192748, 333-192749, 333-200452 and 333-200453) and Form S-8 (Nos. 333-152168, 333-158260, 333-162955, 333-170044, 333-178158, 333-184004, 333-189611 and 333-196510) of our report (which includes an explanatory paragraph as to the Company’s ability to continue as a going concern) dated March 12, 2015, with respect to our audits of the consolidated financial statements of CTI BioPharma Corp. as of December 31, 2014 and 2013 and for the years ended December 31, 2014, 2013 and 2012 and our report dated March 12, 2015 with respect to our audit of the effectiveness of internal control over financial reporting of CTI BioPharma Corp. as of December 31, 2014, which reports are included in this Annual Report on Form 10-K of CTI BioPharma Corp. for the year ended December 31, 2014.
/s/ Marcum llp
Marcum llp
San Francisco, CA
March 12, 2015